Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;55(1):62-75.
doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14.

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

Hendrik Isbarn  1 , Laurent Boccon-Gibod, Peter R Carroll, Francesco Montorsi, Claude Schulman, Matthew R Smith, Cora N Sternberg, Urs E Studer
Affiliations
Review

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

Hendrik Isbarn et al. Eur Urol. 2009 Jan.

Abstract

Context: Androgen deprivation therapy (ADT) is increasingly used for the treatment of prostate cancer (PCa), even in clinical settings in which there is no evidence-based proof of prolonged overall survival (OS). ADT, however, may be associated with numerous side effects, including an increased therapy-related cardiovascular mortality.

Objective: To discuss different clinical settings in which ADT is currently used and to critically weigh the benefits of ADT against its possible side effects.

Evidence acquisition: A MEDLINE search was conducted to identify original articles and review articles addressing the efficacy and side effects of ADT for the treatment of PCa. Keywords consisted of prostate cancer, hormonal therapy, adverse effects, radical prostatectomy, and radiotherapy. The articles with the highest level of evidence for the various examined end points were identified with the consensus of all authors and were reviewed.

Evidence synthesis: Even short-term use of ADT may lead to numerous side effects, such as osteoporosis, obesity, sarcopenia, lipid alterations, insulin resistance, and increased risk for diabetes and cardiovascular morbidity. Despite these side effects, ADT is commonly used in various clinical settings in which a clear effect on improved OS has not been shown.

Conclusions: ADT is associated with an increased risk of multiple side effects that may reduce quality of life and/or OS. Consequently, these issues should be discussed in detail with patients and their families before initiation of ADT. ADT should be used with knowledge of its potential long-term side effects and with possible lifestyle interventions, especially in settings with the highest risk-benefit ratio, to alleviate comorbidities.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Side effects of androgen deprivation therapy (ADT).
See this image and copyright information in PMC

References

    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40. - PubMed
    1. Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–23.
    1. Huggins C. Endocrine-induced regression of cancers. Cancer Res. 1967;27:1925–30. - PubMed
    1. Niehans P. Prostata-Krebs wie Paraprostata-Hypertrophie sind Folgen hormoneller Störungen, die wir je früher je besser beeinflussen können. 1940.
    1. Barry MJ, Delorenzo MA, Walker Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006;98:973–8. - PMC - PubMed

Substances